CASIF · CASI Pharmaceuticals, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 2, 2022; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CASIF
this stock
CASI Pharmaceuticals, Inc.
|
$2.67M | -84.8% | -27.4% | — | 0.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -128 sh
- Top holder
- WEST PACES ADVISORS INC.
Performance
Raw-price comparisons begin at the captured split on Jun 2, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CASIF | -0.9% | -8.0% | -84.3% | -0.9% | -84.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -1.4% | -11.0% | -97.7% | -3.9% | -97.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.